Filing summary
Entity and period: The supplied filing is Colombier Acquisition Corp.’s Form 10-K for February 12, 2021 (inception) through December 31, 2021. It is not a PSQ Holdings, Inc. filing, despite the request metadata. Colombier was a shell company/SPAC with no operating business as of year-end.
Financial results and position
| Metric | Reported amount |
|---|---|
| Operating revenue | None; the company had not commenced operations. |
| Net income | $3.73 million for the inception-to-year-end period. |
| Key income items | $4.91 million gain from the change in fair value of warrant liabilities and $6,512 trust-account interest, offset by $852,175 formation and operating costs and $329,619 offering costs allocated to warrants. |
| Cash used in operating activities | $973,475. |
| Cash and working capital | $841,226 cash and approximately $0.79 million working capital at December 31, 2021; working capital figure includes an adjustment for franchise tax payable. |
| Trust-account securities | $172.51 million, invested primarily in U.S. Treasury securities through money market funds. |
| Liabilities | $12.60 million total, including $6.08 million warrant liabilities and $6.04 million deferred underwriting fees payable if a business combination closes. |
| Public shares subject to redemption | 17.25 million shares recorded as temporary equity at $172.50 million, or $10.00 per share. |
| Debt | No long-term debt reported. A $46,975 non-interest-bearing sponsor note was repaid at the IPO closing. |
Margins are not meaningful because the company had no operating revenue. The filing covers only the company’s first partial year and provides no comparable prior-year operating period.
Business, capital and material changes
- The company raised $172.5 million through its IPO, issuing 17.25 million units at $10 each, and received $5.7 million from private placement warrants. It deposited $172.5 million in the trust account. A $1.24 million trust overfunding caused by a clerical error was transferred to the operating account.
- Offering costs were reported as $9.95 million in the financial-statement note, including $3.45 million paid underwriting fees, $6.04 million deferred fees and other costs. A separate business-section disclosure gives a different total and includes warrant-related costs; investors should reconcile the figures.
- The $3.73 million net income primarily reflects a non-cash warrant fair-value gain, rather than operating performance or recurring revenue.
- The filing reports that previously issued IPO and interim financial statements were restated in 2021 following accounting issues involving complex financial instruments.
Outlook, risks and unusual items
- Management intended to identify and complete a business combination by June 11, 2023. No target or transaction guidance was provided. The company said it expected available working capital and borrowing capacity to support operations through the earlier of a business combination or one year from the filing, while acknowledging funding needs could exceed estimates.
- The sponsor committed to provide up to $100,000 for working-capital and transaction costs if funds outside the trust account were insufficient. Additional financing could be required to complete a transaction or accommodate redemptions; there is no assurance it would be available.
- If no business combination is completed by the deadline, public shares are to be redeemed from the trust account, generally based on the trust value per share, subject to permitted costs, creditor claims and other legal requirements. Warrants would expire worthless.
- Material weakness in internal control over financial reporting related to accounting for complex financial instruments made disclosure controls ineffective at December 31, 2021. Management described planned remediation, but gave no assurance it would be effective. The auditor’s opinion on the financial statements was unqualified; the auditor did not express an opinion on internal-control effectiveness.
- Principal disclosed risks include inability to find or close a target, redemption-related constraints, competition among SPACs, COVID-19 and market volatility, conflicts of interest, potential dilution or transaction debt, creditor claims against trust assets, and NYSE listing requirements.
- Related-party matters include a $10,000 monthly administrative-services arrangement with a sponsor affiliate, expense reimbursements without a stated cap, and possible advisory fees to a sponsor affiliate if engaged. These arrangements and management conflicts merit review.
Investor verification priorities
- Confirm the issuer identity: the filing is for Colombier Acquisition Corp. (CLBR), not PSQ Holdings, Inc.
- Review the restatement disclosures and remediation progress for the complex-financial-instruments material weakness.
- Reconcile offering-cost totals across the filing and verify the treatment and valuation of warrant liabilities.
- Check current trust-account assets, cash available outside the trust, sponsor funding capacity and any subsequent business-combination developments.
- Assess redemption, creditor-claim, sponsor-indemnity and warrant-expiration risks, including the practical value of the sponsor’s indemnity.
- Review related-party payments, potential sponsor-affiliate advisory fees, conflicts of interest and dilution provisions before evaluating any proposed transaction.